<DOC>
	<DOCNO>NCT00540293</DOCNO>
	<brief_summary>To evaluate percentage Korean dyslipidemic subject total group cardiovascular risk group achieve LDL-C target define NCEP ATP Ⅲ criterion start dos 10mg , 20mg 40mg atorvastatin 8 week treatment .</brief_summary>
	<brief_title>Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Is Korean , dyslipidemic outpatient 2 . Is eligible LDLlowering drug therapy screen baseline determine follow LDLcholesterol ( LDLC ) cutoff point define NCEP ATP Ⅲ : 2 . 1 LDLC ≥ 190 mg/dL subject 0 1 CHD risk factor 2 . 2 LDLC ≥ 160 mg/dL subject 2 CHD risk factor 10 year risk &lt; 10 % 2 . 3 LDLC ≥ 130 mg/dL subject 2 CHD risk factor 10 year risk 1020 % 2 . 4 LDLC ≥ 100 mg/dL subject document CHD CHD risk equivalent ( 10year risk &gt; 20 % ) 3 . Has LDLC ≤ 220mg/dL baseline 4 . Has triglyceride level ≤ 600mg/dL baseline 1 . Is pregnant lactate 2 . Has present myopathy history myopathy personal familial history hereditary muscular disorder history rhabdomyolysis 3 . Has history intolerance hypersensitivity atorvastatin statins 4 . Uncontrolled hypertension ( i.e . moderate hypertension , sit systolic BP ≥ 160mmHg and/or diastolic BP ≥ 100mmHg ) 5 . Has HbAlc &gt; 10 % 6 . Has severe disease major problem surgical procedure within 3 month prior screen likely jeopardize plan termination study . ( e.g. , carcinoma , coronary angioplasty , coronary artery bypass graft , cardiac infarct , severe unstable angina pectoris )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>